DFM Platform
DFM Funding Monitor

3D Printing of Ultra-fideLity tissues using Space for anti-ageing solutions on Earthbroad

PULSE · Horizon Europe grant · 2023-04-01–2028-03-31

EC contribution

€4,597,579

Total cost

€4,597,579

Beneficiaries

8
About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2022-PATHFINDEROPEN-01-01. CORDIS record →

Objective

Bioprinting in Space is one of the novel promising and perspective research directions in the rapidly emerging field of biofabrication. There are several advantages of bioprinting in Space. First, under the conditions of microgravity, it is possible to bioprint constructs employing more fluidic channels and, thus, more biocompatible bio-inks. Second, microgravity conditions enable 3D bioprinting of tissue and organ constructs of more complex geometries with voids, cavities, and tunnels. Third, a novel scaffold-free, label-free, and nozzle-free technology based on multi-levitation principles can be implemented under the condition of microgravity. The ideal Space bioprinters must be safe, automated, compact, and user friendly. Thus, there are no doubts that systematic exploration of 3D bioprinting in Space will advance biofabrication and bioprinting technology per se. Vice versa 3D bioprinted tissues could be used to study pathophysiological biological phenomena when exposed to microgravity and cosmic radiation that will be useful on Earth to understand ageing conditioning of tissues, and in space for the crew of deep space manned missions. In PULSE, we aim at developing a radical new bioprinting technology based on multiple levitation principles and to use Space as an accelerator of ageing on Earth. As a proof of concept study, we will use this newly developed bioprinting technology to create cardiac 3D in vitro models able to better mimic cardiac physiology compared to organoids. We will use such models to study cardiac ageing and test the efficacy of antiinflammatory/ anti-oxidative drugs with anti-ageing potential.

Beneficiaries (8)

OrganisationCountryRoleEC contributionSME
UNIVERSITEIT MAASTRICHT NL coordinator €1,407,075
SPACE APPLICATIONS SERVICES NV BE participant €1,160,375 Yes
METATISSUE - BIOSOLUTIONS, LDA PT participant €540,000 Yes
OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG DE participant €479,996
STUDIECENTRUM VOOR KERNENERGIE / CENTRE D'ETUDE DE L'ENERGIE NUCLEAIRE BE participant €428,845
IN SRL IT participant €215,000 Yes
RD INNOVATION APS DK participant €213,062
MEDIZINISCHE UNIVERSITAT GRAZ AT participant €153,225

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries
Sectors
Sources

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.